Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID-19 mild to moderate meta-analysis

Krolewiecki
 
NCT004381884
RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
30/15 inconclusive
    NCT04523831 (Mahmud)
     
    NCT04523831
    RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
    200/200 safety concern
    • suggested 89 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 93 % increase in clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    • suggested 56 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
    • statistically significant 17.6-fold increase in adverse events with a moderate degree of certainty due to some concern in risk of bias
    Shahbaznejad
     
    IRCT20111224008507N3
    RCTivermectinstandard of careCOVID-19 mild to moderatesome concern
    35/38 inconclusive
      4 studies excluded by filtering options (2 RCT / 2 OBS)

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).